Mycio Wealth Partners LLC continued to hold its position in GlaxoSmithKline PLC (NYSE:GSK) during the second quarter, according to its most recent 13F filing with the SEC. The fund owned 84,275 shares of the pharmaceutical company’s stock at the end of the second quarter. GlaxoSmithKline PLC accounts for 0.4% of Mycio Wealth Partners LLC’s holdings, making the stock its 28th largest position. Mycio Wealth Partners LLC’s holdings in GlaxoSmithKline PLC were worth $3,553,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in GSK. Bronfman E.L. Rothschild L.P. increased its position in GlaxoSmithKline PLC by 45.4% in the first quarter. Bronfman E.L. Rothschild L.P. now owns 2,410 shares of the pharmaceutical company’s stock valued at $102,000 after buying an additional 753 shares during the period. Nelson Van Denburg & Campbell Wealth Management Group LLC increased its position in GlaxoSmithKline PLC by 1,747.4% in the first quarter. Nelson Van Denburg & Campbell Wealth Management Group LLC now owns 2,494 shares of the pharmaceutical company’s stock valued at $105,000 after buying an additional 2,359 shares during the period. Proficio Capital Partners LLC increased its position in GlaxoSmithKline PLC by 233.0% in the first quarter. Proficio Capital Partners LLC now owns 2,844 shares of the pharmaceutical company’s stock valued at $122,000 after buying an additional 1,990 shares during the period. Heritage Trust Co purchased a new position in GlaxoSmithKline PLC during the first quarter valued at about $123,000. Finally, Westwood Holdings Group Inc. increased its position in GlaxoSmithKline PLC by 15.7% in the first quarter. Westwood Holdings Group Inc. now owns 2,950 shares of the pharmaceutical company’s stock valued at $124,000 after buying an additional 400 shares during the period. 8.99% of the stock is owned by institutional investors and hedge funds.

GlaxoSmithKline PLC (GSK) traded up 0.03% during mid-day trading on Friday, reaching $39.47. The company’s stock had a trading volume of 1,644,056 shares. The firm has a 50-day moving average of $40.70 and a 200 day moving average of $41.84. The firm has a market capitalization of $96.46 billion, a price-to-earnings ratio of 38.77 and a beta of 1.03. GlaxoSmithKline PLC has a 1-year low of $37.20 and a 1-year high of $44.54.

GlaxoSmithKline PLC (NYSE:GSK) last issued its quarterly earnings results on Wednesday, July 26th. The pharmaceutical company reported $0.70 EPS for the quarter, beating analysts’ consensus estimates of $0.68 by $0.02. The company had revenue of $9.36 billion for the quarter, compared to analyst estimates of $9.52 billion. GlaxoSmithKline PLC had a return on equity of 114.93% and a net margin of 6.48%. Equities analysts expect that GlaxoSmithKline PLC will post $2.84 earnings per share for the current year.

The business also recently announced a quarterly dividend, which will be paid on Thursday, October 12th. Investors of record on Friday, August 11th will be issued a dividend of $0.491 per share. This represents a $1.96 annualized dividend and a yield of 4.98%. The ex-dividend date of this dividend is Wednesday, August 9th. This is a positive change from GlaxoSmithKline PLC’s previous quarterly dividend of $0.46. GlaxoSmithKline PLC’s dividend payout ratio is presently 197.00%.

TRADEMARK VIOLATION WARNING: This report was first published by TheOlympiaReport and is owned by of TheOlympiaReport. If you are reading this report on another website, it was illegally stolen and reposted in violation of United States and international trademark and copyright laws. The legal version of this report can be read at https://theolympiareport.com/2017/08/27/mycio-wealth-partners-llc-has-3553000-stake-in-glaxosmithkline-plc-gsk.html.

Several research analysts recently weighed in on GSK shares. Citigroup Inc. reissued a “neutral” rating on shares of GlaxoSmithKline PLC in a research note on Thursday, July 27th. J P Morgan Chase & Co reissued a “neutral” rating on shares of GlaxoSmithKline PLC in a research note on Wednesday, May 31st. TheStreet downgraded shares of GlaxoSmithKline PLC from a “b” rating to a “c+” rating in a research note on Wednesday, July 26th. Zacks Investment Research raised shares of GlaxoSmithKline PLC from a “hold” rating to a “buy” rating and set a $47.00 target price for the company in a research note on Tuesday, July 18th. Finally, Berenberg Bank raised shares of GlaxoSmithKline PLC from a “hold” rating to a “buy” rating in a research note on Friday, May 26th. Two research analysts have rated the stock with a sell rating, eight have given a hold rating and nine have given a buy rating to the company’s stock. The company currently has an average rating of “Hold” and a consensus price target of $44.67.

GlaxoSmithKline PLC Company Profile

GlaxoSmithKline plc is a global healthcare company. The Company operates through three segments: Pharmaceuticals, Vaccines and Consumer Healthcare. The Company focuses on its research across six areas: Respiratory diseases, human immunodeficiency virus (HIV)/infectious diseases, Vaccines, Immuno-inflammation, Oncology and Rare diseases.

Want to see what other hedge funds are holding GSK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for GlaxoSmithKline PLC (NYSE:GSK).

Institutional Ownership by Quarter for GlaxoSmithKline PLC (NYSE:GSK)

Receive News & Ratings for GlaxoSmithKline PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline PLC and related companies with Analyst Ratings Network's FREE daily email newsletter.